Structure-Based Drug Design (SBDD) has evolved a graphic (Small)great deal over the past 30 years since the concept of the 鈥淟ock and Key鈥� hypothesis was first reduced to practice in the HIV-1 protease field, leading to the rational design of a number of molecules that are at the forefront of effective therapy. Evolution of techniques such as x-ray crystallography, NMR and computational chemistry have enabled a more informed understanding of binding events, encouraging many groups to employ SBDD strategies to a wide range of drug-relevant targets.
Zing鈥檚 inaugural SBDD event will showcase many of the advances made in structural biology, fragment-based methodologies and computational chemistry, demonstrating how these have been used to enable drug discovery programmes in a range of drug target classes from enzymes, to more complex GPCR鈥檚 and PPI鈥檚. The conference will also feature some of the emerging technologies in the field, which will serve as a glimpse into the future of drug discovery as SBDD becomes more diverse and unrestrained.
You will enjoy the opportunity to engage with many of the pace-setters in the SBDD field, leaving with fresh ideas and concepts that will help to continue to build success in your drug discovery efforts.
Zing鈥檚 inaugural SBDD event will showcase many of the advances made in structural biology, fragment-based methodologies and computational chemistry, demonstrating how these have been used to enable drug discovery programmes in a range of drug target classes from enzymes, to more complex GPCR鈥檚 and PPI鈥檚. The conference will also feature some of the emerging technologies in the field, which will serve as a glimpse into the future of drug discovery as SBDD becomes more diverse and unrestrained.
You will enjoy the opportunity to engage with many of the pace-setters in the SBDD field, leaving with fresh ideas and concepts that will help to continue to build success in your drug discovery efforts.
